Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma
…, P Mamindla, S Behr, A Goodman, DL Ploucha… - medRxiv, 2024 - medrxiv.org
Background: Variability in treatment response may be attributable to organ-level
heterogeneity in tumor lesions. Radiomic analysis of medical images can elucidate non-invasive …
heterogeneity in tumor lesions. Radiomic analysis of medical images can elucidate non-invasive …
[HTML][HTML] 588 Phase Ib study of the p38 inhibitor ARRY-614 with nivolumab, ipilimumab or nivolumab+ ipilimumab in advanced solid tumors
…, S Brodeur, J Urban, A Rose, A Goodman, D Ploucha… - 2022 - jitc.bmj.com
Background The p38 mitogen-activated protein kinase (MAPK) pathway limits dendritic cell
priming and we have discovered a novel tumor-intrinsic immune-exclusion role for p38 …
priming and we have discovered a novel tumor-intrinsic immune-exclusion role for p38 …
